Infections in Healthcare Workers

Evidence-Based Infectious Diseases: Second Edition

Volumn , Issue , 2009, Pages 291-301

  Rose, Gregory ^a   Roth, Virginia R ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Effect of postexposure prophylaxis (PEP) on HIV transmission; Healthcare workers at risk of occupational exposure to hepatitis B virus (HBV); HIV infection and risk assessment; Infections in healthcare workers (HCWs); Influenza like illness influenza epidemics and pandemics, remarkable societal impact; Institutional measures to control ILI the SARS experience; Occupational bloodborne pathogen exposures; Rapid HIV testing of source reducing unnecessary use of PEP; Risk factors for HIV seroconversion after percutaneous exposure; Varicella zoster virus (VZV) in causing chickenpox or varicella zoster

Indexed keywords

EID: 78650830208     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444301601.ch18     Document Type: Chapter

References (111)

1. Panlilio AL, Orelien JG, Srivastava PU, et al. Estimate of the annual number of percutaneous injuries among hospital-based healthcare workers in the United States, 1997-1998. Infect Control Hosp Epidemiol 2004; 25: 556-562.
2. Occupational Safety and Health Administration. Record Summary of the Request for Information on Occupational Exposure to Bloodborne Pathogens Due to Percutaneous Injury. (Washington, D.C.: Occupational Safety and Health Administration, May 1999). http://www.osha-slc.gov/html/ndlreport052099.html
3. Prüss-Üstün A, Rapiti E, Hutin Y. Sharps injuries: Global burden of disease from sharps injuries to health-care workers. WHO Environmental Burden of Disease Series, No 3. World Health Organization, Geneva, Switzerland. 2003.
4. Public Health Laboratory Service. Occupational transmission of HIV. Summary of published reports. PHLS, London, UK 1997.
5. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337: 1485-90.
6. Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford G. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. 2007 (1), CD002835, DOI: 10.1002/14651858.
7. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409-14.
8. Tsai CC, Emau P, Sun JC, et al. Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J Med Primatol 2000; 29: 248-58.
9. Le Grand R, Vaslin B, Larghero J, et al. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS 2000; 14: 1864-6.
10. Wang SA, Panlilio AL, Doi PA, White AD, Stek M Jr, Saah A. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol 2000; 21(12): 780-5.
11. Srivastava P, Cardo DM, Panlilio A, Campbell S. Tolerability of antiretroviral agents used by health-care workers (HCWs) as post-exposure prophylaxis (PEP) for occupational exposures to HIV. Int Conf AIDS, 12: 626 (abstract no. 246/33171). 1998.
12. Centers for Disease Control and Prevention. Updated US Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001; 50 RR-11: 1-52.
13. Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR 2005; 54 RR-9: 1-17.
14. King AM, Osterwalder JJ, Vernazza PL. A randomized prospective study to evaluate a rapid HIV-antibody assay in the management of cases of percutaneous exposure amongst health care workers. Swiss Med Wkly 2001; 12: 10-13.
15. Landrum ML, Wilson CH, Perri LP, Hannibal SL, O'Connell RJ. Usefulness of a rapid human immunodeficiency virus-1 antibody test for the management of occupational exposure to blood and body fluid. Infect Control Hosp Epidemiol 2005; 26(9): 768-74.
16. Weller S, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002 (1), CD003255, DOI: 10.1002/14651858.
17. Werner BG, Grady GF. Accidental hepatitis B surface antigen positive inoculations: use of e antigen to estimate infectivity. Ann Intern Med 1982: 97: 367-9.
18. Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev 2005 (4), CD000100, DOI: 10.1002/14651858.
19. Centers for Disease Control and Prevention. Hepatitis Surveillance Report Number 60. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.
20. Averhoff F, Mahoney F, Colemen P, et al. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B infection. Am J Prev Med 1998; 15: 1-8.
21. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565.
22. Hadler SC, Francis DP, Maynard JE, et al. Long-term immu-nogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209-14.
23. Palmovic D, Crnjakovic-Palmovic J. Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules. Infection 1993; 21(1): 42-5.
24. Veterans Administration Cooperative Study. Type B hepatitis after NSI exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978; 88: 285-93.
25. Hoofnagle JH, Seeff LB, Bales ZB, et al. Passive-active immunity from hepatitis B immune globulin. Reanalysis of a Veteran Administration cooperative study of needle-stick hepatitis. Ann Intern Med 1979; 91: 813-18.
26. Beasley RP, Hwang L-Y, Steven CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo controlled trial. Hepatology 1983;3: 135M1.
27. Puro V, De Carli G, Cicalini S et al. European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro Surveill 2005; 10: 260-4.
28. Jagger J, Puro V, De Carli G. Occupational transmission of hepatitis C virus. JAMA 2002; 288: 1469-70.
29. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C infection with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
30. Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39: 1721-31.
31. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632-8.
32. Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43: 923-31.
33. Varghese GM, Abraham OC, Mathai D. Post-exposure prophylaxis for blood borne viral infections in healthcare workers. Postgrad Med J 2003; 79(932): 324-8.
34. Ayas NT, Barger KL, Cade BE, et al. Extended work duration and the risk of self-reported percutaneous injuries in interns. JAMA 2006; 296: 1055-62.
35. Brasel KJ, Mol C, Kolker A, et al. Needlesticks and surgical residents: who is most at risk? J Surg Educ 2007; 64: 395-8.
36. Clarke SP. Hospital work environments, nurse characteristics, and sharps injuries. Am J Infect Control 2007; 35: 302-9.
37. Rogers B, Goodno L. Evaluation of interventions to prevent needlestick injuries in health care occupations. Am J Prev Med 2000; 18: 90-8.
38. Tuma S, Sepkowitz KA. Efficacy of safety-engineered device implementation in the prevention of percutaneous injuries: a review of published studies. Clin Infect Dis 2006; 42: 1159-70.
39. Marin M, Güris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 RR-4: 1-40.
40. Stover BH, Bratcher DF. Varicella-zoster virus: infection, control, and prevention. Am J Infect Control 1998; 26(3): 369-81.
41. Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330: 901-5.
42. Centers for Disease Control and Prevention. Immunization of Health-Care Workers: Recommendations of the Advisory Practices and the Hospital Infection Control Practices Advisory Committee. MMWR 1997;46 (RR-18): 1-43.
43. Wreghitt TG, Whipp J, Redpath C, Hollingworth W. An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987-92. Epidemiol Infect 1996; 117(1): 165-71.
44. Tennenberg AM, Brassard JE, Van Lieu J, Drusin LM. Varicella vaccination for healthcare workers at a university hospital: an analysis of costs and benefits. Infect Control Hosp Epidemiol 1997; 18(6): 405-11.
45. Weber DJ, Rutala WA, Hamilton H. Prevention and control of varicella-zoster infections in healthcare facilities. Infect Control Hosp Epidemiol 1996; 17: 694-705.
46. Health Canada. Prevention and control of occupational infection in health care. CCDR 2002;28S1: 1-264.
47. Yoshikawa T, Ihira M, Suzuki K, Suga S, Tomitaka A, Ueda H, Asano Y. Rapid contamination of the environments with varicella-zoster virus DNA from a patient with herpes zoster. J Med Virol 2001; 63(1): 64-6.
48. Suzuki K, Yoshikawa T, Tomitaka A, Matsunaga K, Asano Y. Detection of aerosolized varicella-zoster virus DNA in patients with localized herpes zoster. J Infect Dis 2004; 189(6): 1009-12.
49. Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 1988; 158(1): 238-41.
50. Saiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol 2001; 22: 279-83.
51. Alter SJ, Hammond JA, McVey CJ, Myers MG. Susceptibility to varicella-zoster virus among adults at high risk for exposure. Infect Control 1986; 7(9): 448-51.
52. Ferson MJ, Bell SM, Robertson PW. Determination and importance of varicella immune status of nursing staff in a children's hospital. J Hosp Infect 1990; 15: 347-51.
53. Vandersmissen G, Moens G, Vranckx R, et al. Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: a seroprevalence study. Occup Environ Med 2000; 57: 621-6.
54. Gallagher J, Quaid B, Cryan B. Susceptibility to varicella zoster virus infection in health care workers. Occup Med (Lond) 1996: 46: 289-92.
55. McKinney WP, Horowitz MM, Battiola RJ. Susceptibility of hospital-based health care personnel to varicella-zoster virus infections. Am J Infect Control 1989; 17(1): 26-30.
56. Santos AM, Ono E, Weckx LY, Coutinho AP, de Moraes-Pinto MI. Varicella zoster antibodies in healthcare workers from two neonatal units in São Paulo, Brazil-assessment of a staff varicella policy. J Hosp Infect 2004; 56(3): 228-31.
57. Almuneef MA, Memish ZA, Balkhy HH, et al. Seroprevalence survey of varicella, measles, rubella, and hepatitis A and B viruses in a multinational healthcare workforce in Saudi Arabia. Infect Control Hosp Epidemiol 2006: 27: 1178-83.
58. Gray AM, Fenn P, Weinberg J, et al. An economic analysis of varicella vaccination for health care workers. Epidemiol Infect 1997; 119: 209-20.
59. Gayman J. A cost-effectiveness model for analysing two varicella vaccination strategies. Am J Health Syst Pharm 1998; 15: S4-8.
60. Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21: 13-38.
61. Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax®) in healthy adolescents and adults. Vaccine 1995; 13: 967-72.
62. Gershon AA, Steinberg SP, LaRussa P, et al. NIAID Varicella Vaccine Collaborative Study Group. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988; 158: 132-7.
63. Ferson MJ. Varicella vaccine in post-exposure prophylaxis. Commun Dis Intell 2001; 25(1): 13-15.
64. Balfour HH Jr, Groth KE, McCullough J, et al. Prevention or modification of varicella using zoster immune plasma. Am J Dis Child 1977; 131: 693-6.
65. Orenstein WA, Heymann DL, Ellis RJ, et al. Prophylaxis of varicella in high risk children: dose response effect of zoster immune globulin. J Pediatr 1981; 98: 368-73.
66. Zaia J, Levin MJ, Preblud SK, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147: 737-43.
67. Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet 1989; 2: 371-3.
68. White CB, Hawley WZ, Harford DJ, et al. The pediatric resident susceptible to varicella: providing immunity through postexposure prophylaxis with oral acyclovir. Pediatr Infect Dis J 1994; 13: 743-4.
69. Asano Y, Yoshikawa T, Suga S, et al. Post-exposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993; 92: 219-22.
70. Lin TY, Huang YC, Ning HC, et al. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997; 16: 1162-5.
71. Maeda A, Hisakawa H, Wakiguchi H, Kurashige T. An immunocompetent child with herpes zoster following postexposure prophylaxis of varicella by oral acyclovir. Acta Paediatr 1999; 88(10): 1161-2.
72. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999;44 Suppl B: 11-15.
73. Hansen S, Stamm-Balderjahn S, Zuschneid I, et al. Closure of medical departments during nosocomial outbreaks: data from a systematic analysis of the literature. J Hosp Infect 2007; 65(4): 348-53.
74. Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol 2002; 23(10): 615-19.
75. Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007 (2), CD001269, DOI: 10.1002/14651858.
76. Burls A, Jordan R, Barton P, Olowokure B, Wake B, Albon E, Hawker J. Vaccinating healthcare workers against influenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 2006; 24(19): 4212-21.
77. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281: 908-13.
78. Saxén H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18(9): 779-83.
79. Weingarten S, Staniloff H, Ault M, Miles P, Bamberger M, Meyer RD. Do hospital employees benefit from the influenza vaccine? A placebo-controlled clinical trial. J Gen Intern Med 1988; 3(1): 32-7.
80. Thomas RE, Jefferson T, Demicheli V, Rivetti D. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2006 (3), CD005187, DOI: 10.1002/14651858.
81. Hofmann F, Ferracin C, Marsh G, Dumas R. Influenza vaccination of healthcare workers: a literature review of attitudes and beliefs. Infection 2006; 34(3): 142-7.
82. Dey P, Halder S, Collins S, et al. Promoting uptake of influenza vaccination among health care workers: a randomized controlled trial. J Public Health Med 2001; 23: 346-8.
83. Steckel CM. Mandatory influenza immunization for health care workers-an ethical discussion. AAOHN J 2007; 55(1): 34-9.
84. Aoki FY, Yassi A, Cheang M, et al. Effects of acetaminophen on adverse effects of influenza vaccination in health care workers. CMAJ 1993; 149: 1425-30.
85. Jefferson T, Demisheli V, Di Pietrantonj C, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006 (3), CD001265, DOI: 10.1002/14651858.
86. Jefferson T, Demicheli V, Di Pietrantonj C, et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006 (2), CD001169, DOI: 10.1002/14651858.
87. Fiore A, Shay DK, Haber P, et al. Prevention and control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2007. MMWR 2007; 56 RR-06: 1-54.
88. Svoboda T, Henry B, Shulman L, et al. Public health measures to control the spread of the Severe Acute Respiratory Syndrome during the outbreak in Toronto. N Engl J Med 2004; 350: 2352-61.
89. Teleman MD, Boudville IC, Heng BH, et al. Factors associated with transmission of severe acute respiratory syndrome among health-care workers in Singapore. Epidemiol Infect 2004; 132: 797-803.
90. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. World Health Organization Geneva, Switzerland 2004. Online at http://www.who.int/csr/sars/country/table2004_04_21/en/index.html, accessed March 17, 2008.
91. Varia M, Wilson S, Sarwal S, et al. Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. CMAJ 2003; 169: 285-92.
92. Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings, CDC, Atlanta USA, June 2007, available at http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf. Accessed March 2008.
93. White C, Kolble R, Carlson R, et al. The effect of hand hygiene on illness rate among students in university residence halls. Am J Infect Control 2003; 31(6): 364-70.
94. Mott PJ, Sisk BW, Arbogast JW, et al. Alcohol-based instant hand sanitizer use in military settings: a prospective cohort study of Army basic trainees. Mil Med 2007; 172: 1170-6.
95. Ejemot RI, Ehiri JE, Meremikwu MM, Critchley JA. Handwashing for preventing diarrhoea. Cochrane Database Syst Rev 2008;1: CD004265, DOI: 10.1002/14651858.
96. Haas JP, Larson EL. Measurement of compliance with hand hygiene. J Hosp Infect 2007; 66: 6-14.
97. Manian FA, Ponzillo JJ. Compliance with routine use of gowns by healthcare workers (HCW) and non-HCW visitors on entry into the rooms of patients under contact precautions. Infect Control Hosp Epidemiol 2007; 28: 337-40.
98. Aronsson G, Gustafsson K, Dallner M. Sick but yet at work. An empirical study of sickness presenteeism. J Epidemiol Community Health 2000; 54(7): 502-9.
99. Atkinson WL, Markowitz LE, Adams NC, et al. Transmission of measles in medical settings-United States, 1985089. Am J Med 1991; 91: 320-4S.
100. Ferson MJ, Roberston PW, Whybin LR. Cost-effectiveness of prevaccination screening of healthcare workers for immunity to measles, rubella and mumps. Med J Aust 1994; 18: 478-82.
101. Sellick JA Jr, Longbine D, Schideling R, et al. Screening hospital employees for measles immunity is more cost-effective than blind immunization. Ann Intern Med 1992; 116: 982-4.
102. Stover BH, Adams G, Keubler CA, et al. Measles-mumps-rubella immunization of susceptible hospital employees during a community measles outbreak: cost-effectiveness and protective efficacy. Infect Control Hosp Epidemiol 1994; 15: 18-21.
103. Ziegler E, Roth C, Wreghitt T. Prevalence of measles susceptibility among health care workers in a UK hospital. Does the UK need to introduce a measles policy for its healthcare workers? Occup Med (Lond) 2003; 53: 398-402.
104. Hennessey KA, Ion-Nedeleu N, Craciun MD, et al. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies. Am J Epidemiol 1999; 150: 1250-7.
105. Rivest P, Bedard L, Arruda H, et al. Risk factors for measles and vaccine efficacy during an epidemic in Montreal. Can J Pub Health 1995; 86: 86-90.
106. Janaszek W, Gay NJ, Gut W. Measles vaccine efficacy during an epidemic in 1998 in the highly vaccinated population of Poland. Vaccine 2003; 21: 473-8.
107. Correia J, Hart C. Meningococcal disease. BMJ Clinical Evidence. Search date March 2008. BMJ Publishing.
108. Gilmore A, Stuart J, Andrews N. Risk of secondary meningococcal disease in healthcare workers. Lancet 2000; 356: 1654-5.
109. Schwartz B, Al-Tobaiqi Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis. Lancet 1988; 1: 1239-42.
110. Dwarozack DL, Sanders CC, Horowitz EA, et al. Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers. Antimicrob Agents Chemother 1988; 32: 1740-1.
111. Centers for Disease Control and Prevention. Laboratory-acquired meningococcal disease-United States, 2000. MMWR 2002; 51: 141-4.